Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Abivax SA (OTC: AAVXF).

Full DD Report for AAVXF

You must become a subscriber to view this report.

Recent News from (OTC: AAVXF)

Abivax receives DSMB recommendation to continue ongoing extension study in UC patients
Abivax ( OTCPK:AAVXF ) announces that the Data Safety Monitoring Board (DSMB) has recommended continuation of its ongoing 12-month extension study, ABX464-102, continuing its completed placebo-controlled Phase 2a induction trial, ABX464-101. More news on: Abivax SA, Healthcare stocks new...
Source: SeekingAlpha
Date: December, 06 2018 07:40
Your Daily Pharma Scoop: Novocure's Mesothelioma Success, Sangamo's Mixed Results, China's First Homegrown Onco Med
News in focus: NVCR, SGMO Novocure +9.1% after mesothelioma trial shows survival boost Discussion : Novocure ( NVCR ), a midcap biopharma with about $4bn in market capitlization, has seen a tripling of its valuation this year on the back of a slew of positive news. Just about a year a...
Source: SeekingAlpha
Date: September, 06 2018 16:09
Abivax UC candidate shows positive action in mid-stage study
A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,...
Source: SeekingAlpha
Date: September, 05 2018 12:17
An Eye On Biotech - Today's Editors' Picks
We're back! I'm your curator, Michael Hopkins. We have some ideas from the biotech side, along with a healthcare REIT. Today, contributors like Brad Thomas , William Meyers , and BZ Equity Research are in the Editors' Picks spotlight. Here are today's Editors' Picks: Long Ideas ...
Source: SeekingAlpha
Date: April, 26 2018 07:35
A New Generation Of Novel HIV Small-Molecule Antivirals
Introduction HIV therapeutics have undergone a substantial evolution since its inception over three decades ago. From the first controversial FDA-approved drug, Retrovir ((AZT)) to today's newest life-saving combination antiretroviral therapies, HIV therapy has seen incredible progress. Desp...
Source: SeekingAlpha
Date: April, 25 2018 10:19
Abivax SA reports 1H results
Abivax SA ( OTCPK:AAVXF ): 1H Net loss of €5.55 More news on: Abivax SA, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: September, 20 2017 12:39


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AAVXF.

About Abivax SA (OTC: AAVXF)

Logo for Abivax SA (OTC: AAVXF)

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral and inflammatory disease.


Contact Information



Current Management

  • Hartmut J. Ehrlich / CEO
  • Didier Blondel / CFO
  • Philippe Pouletty / Chairman
  • Joy A. Amundson /
  • JeanJacques Bertran /
  • Claude Bertrand /
  • Dominique Costantini /
  • Antonino Ligresti /
  • Antoine Pau /
  • Christian Pierret /
  • JeanPaul Prieels /

Current Share Structure

  • Market Cap: $96,046,260 - 03/20/2018
  • Issue and Outstanding: 9,741,000 - 12/31/2016


Daily Technical Chart for (OTC: AAVXF)

Daily Technical Chart for (OTC: AAVXF)

Stay tuned for daily updates and more on (OTC: AAVXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AAVXF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AAVXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AAVXF and does not buy, sell, or trade any shares of AAVXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: